Thrombembolic risks and bleeding risks
A disturbance of the primary hemostasis or the coagulation cascade (caused for example by mutations of proteins, factor deficiency or drugs) may lead to either a hypocoagulable or a hypercoagulable state, both connected with possible severe health consequences such as bleeding issues or an increased thromboembolic risks.
Pentapharm products are either starting materials for reagent production or ready-to –use reagents for diagnostic analysis of the various components of the coagulation and fibrinolysis system including the Protein C pathway.
Our diagnostic product portfolio includes specific synthetic peptide substrates for determination of the key enzymes in coagulation, enzyme inhibitors to increase substrate specificity, purified snake venom enzymes for the specific activation of enzymes as well as semifinished reagents and IVD diagnostic kits.
Pentapharm is serving a wide range of customers from research in university and industry labs, to manufacturers of diagnostic products and clinical laboratories.